---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-012018"
form_type: "8-K"
ticker: "IVVD"
cik: "0001832038"
company_name: "Invivyd, Inc."
filed_at: "2025-02-03T23:59:59+00:00"
generated_at: "2026-05-27T04:06:11.710037+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Invivyd reports preliminary Q4 revenue of $13.8M; positive Phase 1/2 data for VYD2311

## Summary
- Preliminary Q4 PEMGARDA net revenue $13.8M, 48% growth over Q3; total operating costs $32M, 55% reduction.
- Cash and equivalents $69.3M; accounts receivable $10.9M; targets near-term profitability by end of 1H 2025.
- Positive Phase 1/2 data for VYD2311: safety mild/moderate, serum concentrations high at Day 65, half-life not reached.
- VYD2311 shows average 17-fold greater in vitro neutralization potency vs pemivibart across contemporary SARS-CoV-2 variants.
- Potential clinical profile: 70-90% protection from symptomatic COVID-19 with once- or twice-annual dosing, also as treatment.

## SEC filing metadata
- accession: 0000950170-25-012018
- form_type: 8-K
- ticker: IVVD
- cik: 0001832038
- company_name: Invivyd, Inc.
- filed_at: 2025-02-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1832038/000095017025012018/0000950170-25-012018-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1832038/000095017025012018/ivvd-20250203.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-012018
- JSON: https://secwatch.observer/filing/0000950170-25-012018.json
- Plain text: https://secwatch.observer/filing/0000950170-25-012018.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.